Compare Dell Technologies Inc (DELL) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dell Technologies Inc vs DexCom, Inc. — how do they compare? Dell Technologies Inc trades at $483.69 (market cap $284.93B), while DexCom, Inc. trades at $90.63 (market cap $33.79B). The key difference: Dell Technologies Inc is far larger — about 8.4× DexCom, Inc.'s market cap, and Dell Technologies Inc pays a 0.57% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DELL | DXCM | |
|---|---|---|
Market Cap | $284.93B | $33.79B |
Sector | Technology | Health |
52-Week High | $467.27 | $89.53 |
52-Week Low | $111.10 | $54.84 |
Enterprise Value | $304.51B | $33.24B |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dell Technologies stock trades at $478.30, up 4.45% in the last session, reflecting strong momentum amid AI-driven server demand. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $4.86 surpassing the $2.96 forecast. The technical outlook is bullish, with the price above key moving averages, while fundamentals show revenue growth to $95.57 billion in 2025 and a net income margin of 6.28%.
The outlook remains positive given robust analyst sentiment, with a consensus price target of $503.76 implying upside. Key risks include valuation concerns at a P/E of 35.14 and potential margin pressure from memory shortages. Continued execution on AI server backlog and commercial PC refresh cycles are critical for sustained growth.
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
